Cetuximab, irinotecan and fluorouracile in fiRst-line treatment of immunologically-selected advanced colorectal cancer patients: the CIFRA study protocol

Cetuximab, irinotecan and fluorouracile in fiRst-line treatment of immunologically-selected advanced colorectal cancer patients: the CIFRA study protocol

Abstract Background Combination of chemotherapies (fluoropirimidines, oxaliplatin and irinotecan) with biologic drugs (bevacizumab, panitumumab, cetuximab) have improved clinical responses and survival of metastatic colorectal cancer (mCRC). However, patients’ selection thorough the identification o...

Full description

Bibliographic Details
Main Authors: Alessandro Ottaiano, Stefania Scala, Nicola Normanno, Maria Napolitano, Monica Capozzi, Anna Maria Rachiglio, Cristin Roma, Anna Maria Trotta, Crescenzo D’Alterio, Luigi Portella, Carmela Romano, Antonino Cassata, Rossana Casaretti, Lucrezia Silvestro, Anna Nappi, Salvatore Tafuto, Antonio Avallone, Alfonso De Stefano, Mario Tamburini, Carmine Picone, Antonella Petrillo, Francesco Izzo, Raffaele Palaia, Vittorio Albino, Alfonso Amore, Andrea Belli, Ugo Pace, Massimiliano Di Marzo, Paolo Chiodini, Gerardo Botti, Gianfranco De Feo, Paolo Delrio, Guglielmo Nasti
Format: Article
Language:English
Published: BMC 2019-09-01
Series:BMC Cancer
Subjects:
Colorectal Cancer
Antibody-dependent cell-mediated cytotoxicity
Cetuximab
Irinotecan
Fluorouracule
FcγR
Online Access:http://link.springer.com/article/10.1186/s12885-019-6109-z

Internet

http://link.springer.com/article/10.1186/s12885-019-6109-z

Similar Items